Drug profile · INN
choriogonadotropin alfa
OVIDREL
choriogonadotropin alfa (OVIDREL) is a luteinizing hormone/choriogonadotropin receptor agonist. Associated with Merck KGaA, Darmstadt, Germany. Route of administration: injection. Current US regulatory status: approved.
Drug details — choriogonadotropin alfa
- US status
- approved
- Class
- Genito-urinary system and sex hormones (G03)
- Route
- INJECTION
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
choriogonadotropin alfa (OVIDREL) is a luteinizing hormone/choriogonadotropin receptor agonist. Associated with Merck KGaA, Darmstadt, Germany. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Luteinizing hormone/Choriogonadotropin receptor agonist
Primary target: Lutropin-choriogonadotropic hormone receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is choriogonadotropin alfa?
choriogonadotropin alfa (OVIDREL) is a luteinizing hormone/choriogonadotropin receptor agonist. Associated with Merck KGaA, Darmstadt, Germany. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for choriogonadotropin alfa?
OVIDREL is a marketed brand name for choriogonadotropin alfa. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of choriogonadotropin alfa?
choriogonadotropin alfa has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.